REDWOOD CITY, Calif., Feb. 26, 2016 -- Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it will present at the Cowen and Company 36th Annual Healthcare Conference on Tuesday, March 8 at 10:00 am ET in Boston, Massachusetts.
A webcast of the presentation will be available on the Investors page of the Coherus website at http://investors.coherus.com.
About Coherus BioSciences, Inc.
Coherus is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products, including CHS-5217 (bevacizumab biosimilar) and CHS-3351 (ranibizumab biosimilar). For additional information, please visit www.coherus.com.
CONTACT: Keith Vendola, M.D. Investor Relations Coherus BioSciences, Inc. [email protected] +1 (650) 437-6239


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Anta Sports Expands Global Footprint With Strategic Puma Stake
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 



